JP2022515838A5 - - Google Patents
Info
- Publication number
- JP2022515838A5 JP2022515838A5 JP2021537818A JP2021537818A JP2022515838A5 JP 2022515838 A5 JP2022515838 A5 JP 2022515838A5 JP 2021537818 A JP2021537818 A JP 2021537818A JP 2021537818 A JP2021537818 A JP 2021537818A JP 2022515838 A5 JP2022515838 A5 JP 2022515838A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862785899P | 2018-12-28 | 2018-12-28 | |
| US62/785,899 | 2018-12-28 | ||
| PCT/US2019/068328 WO2020139830A2 (en) | 2018-12-28 | 2019-12-23 | Treatment of respiratory disorders with arachidonate15-lipoxygenase (alox15) inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022515838A JP2022515838A (ja) | 2022-02-22 |
| JPWO2020139830A5 JPWO2020139830A5 (https=) | 2022-12-13 |
| JP2022515838A5 true JP2022515838A5 (https=) | 2022-12-13 |
Family
ID=69326713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021537818A Pending JP2022515838A (ja) | 2018-12-28 | 2019-12-23 | アラキドン酸１５－リポキシゲナーゼ（ａｌｏｘ１５）阻害剤による呼吸器障害の治療 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12472241B2 (https=) |
| EP (1) | EP3902567A2 (https=) |
| JP (1) | JP2022515838A (https=) |
| KR (1) | KR20210110623A (https=) |
| CN (1) | CN113423435A (https=) |
| AU (1) | AU2019417718B2 (https=) |
| CA (1) | CA3124670A1 (https=) |
| IL (1) | IL284046A (https=) |
| MX (1) | MX2021007938A (https=) |
| NZ (1) | NZ777336A (https=) |
| SG (1) | SG11202106517WA (https=) |
| WO (1) | WO2020139830A2 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3911632A1 (en) | 2019-01-15 | 2021-11-24 | Empirico Inc. | Prodrugs of alox-15 inhibitors and methods of using the same |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5932425A (en) | 1997-02-18 | 1999-08-03 | Signal Pharmaceuticals, Inc. | Compositions and methods for modulating cellular NF-κB activation |
| US6297248B1 (en) | 1997-04-06 | 2001-10-02 | Suntory Limited | 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor |
| FR2762841B1 (fr) | 1997-04-30 | 1999-07-02 | Jouveinal Inst Rech | Diazepino-indolones inhibitrices de phosphodiesterases iv |
| IT1296984B1 (it) | 1997-12-19 | 1999-08-03 | Zambon Spa | Derivati ftalazinici inibitori della fosfodiesterasi 4 |
| TR200003130T2 (tr) | 1998-04-28 | 2001-01-22 | Arzneimittelwerk Dresden Gmbh | Yeni hidroksiindoller, bunların fosfodiesteraz 4 inhibitörleri olarak kullanımları ve hazırlanmaları için işlemler |
| US6303789B1 (en) | 1998-06-10 | 2001-10-16 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Benzamides with tetrahydrofuranyloxy substitutents as phosphodiesterase 4 inhibitors |
| IT1302677B1 (it) | 1998-10-15 | 2000-09-29 | Zambon Spa | Derivati benzazinici inibitori della fosfodiesterasi 4 |
| IT1303272B1 (it) | 1998-10-29 | 2000-11-06 | Zambon Spa | Derivati triciclici inibitori della fosfodiesterasi 4 |
| US6686502B1 (en) | 1999-03-26 | 2004-02-03 | Ucb S.A. | Compounds and methods for treatment of asthma, allergy and inflammatory disorders |
| US6740666B2 (en) | 2000-12-20 | 2004-05-25 | Merck & Co., Inc. | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors |
| JP4460221B2 (ja) | 2001-05-24 | 2010-05-12 | メルク フロスト カナダ リミテツド | １−ビアリール−１，８−ナフチリジン−４−オン系ホスホジエステラーゼ−４阻害薬 |
| JO2311B1 (en) | 2001-08-29 | 2005-09-12 | ميرك فروست كندا ليمتد | Alkyl inhibitors Ariel phosphodiesterase-4 |
| AR037517A1 (es) | 2001-11-05 | 2004-11-17 | Novartis Ag | Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria |
| IS7839A (is) | 2002-11-22 | 2004-05-23 | Merck Frosst Canada Ltd. | 4-oxó-1-(3-setið fenýl-1,4-díhýdró-1,8-naftýridín-3-karboxamíð fosfódíesterasa-4 hindrar |
| MY141255A (en) | 2003-12-11 | 2010-03-31 | Memory Pharm Corp | Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs |
| EP2959899B1 (en) | 2011-08-23 | 2017-02-22 | Cornerstone Therapeutics Inc. | Use of zileuton for the treatment of nasal polyps in cystic fibrosis patients |
| US10132809B2 (en) | 2012-10-10 | 2018-11-20 | Rhote Island Hospital | Differential expression of protein markers for the diagnosis and treatment of eosinophilic esophagitis |
| AU2014284235C1 (en) | 2013-06-21 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Methods for treating nasal polyposis by administering an IL-4R antagonist |
| US20210361693A1 (en) | 2018-02-09 | 2021-11-25 | Empirico Inc. | Process to inhibit or eliminate eosinophilic diseases of the airway and related conditions |
-
2019
- 2019-12-23 NZ NZ777336A patent/NZ777336A/en unknown
- 2019-12-23 CA CA3124670A patent/CA3124670A1/en active Pending
- 2019-12-23 KR KR1020217023172A patent/KR20210110623A/ko active Pending
- 2019-12-23 JP JP2021537818A patent/JP2022515838A/ja active Pending
- 2019-12-23 MX MX2021007938A patent/MX2021007938A/es unknown
- 2019-12-23 US US16/725,309 patent/US12472241B2/en active Active
- 2019-12-23 SG SG11202106517WA patent/SG11202106517WA/en unknown
- 2019-12-23 WO PCT/US2019/068328 patent/WO2020139830A2/en not_active Ceased
- 2019-12-23 CN CN201980090028.XA patent/CN113423435A/zh active Pending
- 2019-12-23 EP EP19843006.8A patent/EP3902567A2/en active Pending
- 2019-12-23 AU AU2019417718A patent/AU2019417718B2/en active Active
-
2021
- 2021-06-15 IL IL284046A patent/IL284046A/en unknown
-
2025
- 2025-10-21 US US19/364,245 patent/US20260097102A1/en active Pending